Effect of filaggrin loss-of-function mutations on atopic dermatitis in young age: a longitudinal birth cohort study.
Journal
Journal of human genetics
ISSN: 1435-232X
Titre abrégé: J Hum Genet
Pays: England
ID NLM: 9808008
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
17
12
2018
accepted:
30
05
2019
revised:
12
05
2019
pubmed:
30
6
2019
medline:
26
12
2019
entrez:
29
6
2019
Statut:
ppublish
Résumé
Atopic dermatitis (AD) is a chronic inflammatory skin disease, and skin barrier defects are often observed in patients with AD. So far, few association studies between FLG loss-of-function mutations and onset of AD in longitudinal studies of early childhood have been reported. In the present study, we aimed to investigate the effect of FLG loss-of-function mutations on the development of AD in a longitudinal birth cohort study. The status of AD diagnosis at each age until 6 years was collected from the Tokyo Children's Health, Illness, and Development (T-CHILD) study. We analyzed eight loss-of-function mutations in FLG in 712 participants. FLG loss-of-function mutations were significantly associated with AD onset in infancy (≤2 years) (P < 0.001, OR 3.54, 95% CI 1.88-6.65), but not with AD onset in childhood (≥3 years) (P = 0.981, OR 0.99, 95% CI 0.29-3.36), and none of the children in the present cohort who developed AD at 5 years of age or later carried FLG loss-of-function mutations. Our data support the notion that the effect of FLG loss-of-function mutations is prominent during a very early stage of life.
Identifiants
pubmed: 31249362
doi: 10.1038/s10038-019-0628-y
pii: 10.1038/s10038-019-0628-y
doi:
Substances chimiques
FLG protein, human
0
Filaggrin Proteins
0
S100 Proteins
0
Types de publication
Journal Article
Multicenter Study
Pragmatic Clinical Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-917Références
J Invest Dermatol. 2007 Mar;127(3):724-6
pubmed: 17096018
Allergy. 2014 Apr;69(4):537-40
pubmed: 24467288
Br J Dermatol. 2015 Feb;172(2):455-61
pubmed: 25314673
Allergol Int. 2016 Jul;65(3):327-31
pubmed: 27038776
Nat Genet. 2006 Mar;38(3):337-42
pubmed: 16444271
J Invest Dermatol. 2007 Jul;127(7):1667-72
pubmed: 17301831
J Am Acad Dermatol. 2010 Oct;63(4):587-93
pubmed: 20692725
J Dermatol Sci. 2016 Nov;84(2):144-148
pubmed: 27523805
Trials. 2017 Jul 21;18(1):343
pubmed: 28732519
Pediatr Allergy Immunol. 2004 Jun;15(3):221-9
pubmed: 15209954
J Allergy Clin Immunol. 2015 Apr;135(4):930-5.e1
pubmed: 25618747
Eur Respir J. 2007 Mar;29(3):516-21
pubmed: 17215318
J Cell Sci. 2009 May 1;122(Pt 9):1285-94
pubmed: 19386895
J Allergy Clin Immunol. 2014 Oct;134(4):824-830.e6
pubmed: 25282564
J Allergy Clin Immunol. 2008 Apr;121(4):872-7.e9
pubmed: 18325573
Skin Pharmacol Physiol. 2016;29(3):111-8
pubmed: 27161444
J Allergy Clin Immunol. 2007 Feb;119(2):434-40
pubmed: 17291859
Eur Respir J. 1995 Mar;8(3):483-91
pubmed: 7789502
Allergol Int. 2017 Apr;66(2):230-247
pubmed: 28209325
J Dermatol Sci. 2017 May;86(2):90-96
pubmed: 28108060
Curr Allergy Asthma Rep. 2008 Jul;8(4):299-305
pubmed: 18606081
J Invest Dermatol. 2010 Dec;130(12):2834-6
pubmed: 20686498
N Engl J Med. 2008 Apr 3;358(14):1483-94
pubmed: 18385500